News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team with Recruitment of AstraZeneca PLC (AZN) and Merck & Co., Inc. (MRK) Scientists

2/18/2011 9:52:15 AM

Nottingham, UK – 18th February 2011 – Sygnature Chemical Services Ltd., a leading provider of integrated drug discovery services, today gave an up-date on its recruitment activities. Due to an unprecedented demand for its services from clients in the USA and Europe, over the preceding six months Sygnature has recruited a further 15 experienced medicinal chemists, including significant numbers from AstraZeneca R&D Charnwood in Loughborough and Merck in Newhouse. Sygnature now employs 40 medicinal chemists in its modern, purpose-built facility in BioCity Nottingham.

Commenting on the success of the recent recruitment drive, Dr Simon Hirst, Sygnature’s CEO said, “We are delighted to have been able to attract a substantial number of graduate and PhD qualified medicinal chemists with between 8 – 22 years drug discovery experience in major pharmaceutical companies. AstraZeneca's research facility, located nearby in Loughborough, specialises in R&D for inflammatory respiratory diseases and is a major employer in the East Midlands region. The Merck site in Newhouse, Scotland, specialised in CNS disease R&D. The expertise brought by the new chemists complements what we already had in-house and further strengthens our drug discovery know-how and expertise in asthma, chronic obstructive pulmonary disease, neurodegeneration, psychiatry and pain. I am confident that the addition to these experienced chemists will help fuel our continued growth through 2011 and beyond.”

Dr Prem Meghani who also recently joined Sygnature as a Scientific Group Leader from AstraZeneca commented, “I am pleased to be working at Sygnature with some of my former AZ colleagues. Sygnature is a dynamic working environment and it is great to be applying our combined drug discovery experience to clients’ discovery programmes. Sygnature is fast becoming a major player in medicinal chemistry-driven drug discovery. The addition of more scientists with big pharma experience to the Sygnature team broadens and expands our in-house drug discovery capability.”

About Sygnature Chemical Services Ltd.

Sygnature Chemical Services, founded in 2004, is a leading United Kingdom-based provider of integrated drug discovery services to the global pharmaceutical industry. Key capabilities include medicinal chemistry, synthetic chemistry and computational chemistry. ADME/toxicology services are provided through a strategic alliance with Cyprotex Discovery. Sygnature applies in-house drug discovery expertise, intellectual input and ‘state-of-the-art’ technologies to discover novel drug candidates for its clients. We have a growing team of industry-experienced scientists (80% with PhDs) who are able to undertake key elements of the drug discovery process, including hit finding, hit-to-lead and lead optimisation, to afford novel compounds in a time-efficient and cost-effective manner. Sygnature works closely with its clients to accelerate their drug candidates into development, and thereby increase the value of their programmes. Over the past seven years, Sygnature has built an international client base and established an enviable track record of success in the pharmaceutical industry. For more information on Sygnature, visit .

Contact: Dr Simon Hirst Chief Executive Officer Sygnature Chemical Services Ltd. Tel: +44 (0)115 941 5401 Email:

© 2011 Sygnature Chemical Services Ltd. All rights reserved.

Sygnature Chemical Services Ltd. is a company incorporated in England, with company number 05210563, whose registered office and principal place of business is at BioCity, Pennyfoot Street, Nottingham, NG1 1GF, United Kingdom.

Read at

comments powered by Disqus